PDF(Pubmed)
Abstract：
UNASSIGNED: The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated.
UNASSIGNED: In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.
UNASSIGNED: A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43-13.33]) months and the median overall survival was 16.8 (95% CI [13.3-27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure.
UNASSIGNED: WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.
UNASSIGNED: In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.
UNASSIGNED: A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43-13.33]) months and the median overall survival was 16.8 (95% CI [13.3-27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure.
UNASSIGNED: WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.
摘要：
■全脑放射治疗（WBRT）加同时整合增强（SIB）在乳腺癌脑转移中的作用尚未得到证实。
■在这项单中心回顾性研究中，我们回顾了连续的乳腺癌患者,这些患者发生了脑转移,并接受了使用调强放疗(IMRT)-SIB方法的大分割放疗加WBRT治疗.我们分析了临床结果，治疗失败的预后因素和模式。
■共有27名患者符合分析条件。4例（14.8％）患者获得了临床完全缓解，14例（51.9％）的脑部病变部分缓解。其他9名患者未评估脑肿瘤反应。中位脑无进展生存期为8.60(95%CI[6.43-13.33])个月，中位总生存期为16.8(95%CI[13.3-27.7])个月。三名患者在现场失败，五个有场外故障，两个有场内和场外故障。
■WBRT加SIB改善了乳腺癌脑转移患者的肿瘤控制和临床预后。
■在这项单中心回顾性研究中，我们回顾了连续的乳腺癌患者,这些患者发生了脑转移,并接受了使用调强放疗(IMRT)-SIB方法的大分割放疗加WBRT治疗.我们分析了临床结果，治疗失败的预后因素和模式。
■共有27名患者符合分析条件。4例（14.8％）患者获得了临床完全缓解，14例（51.9％）的脑部病变部分缓解。其他9名患者未评估脑肿瘤反应。中位脑无进展生存期为8.60(95%CI[6.43-13.33])个月，中位总生存期为16.8(95%CI[13.3-27.7])个月。三名患者在现场失败，五个有场外故障，两个有场内和场外故障。
■WBRT加SIB改善了乳腺癌脑转移患者的肿瘤控制和临床预后。
